To view a copy of this licence, visit About this article Cite this article Hsu, CY., Ahmad, I., Maya, R.W
Semaglutide, whether delivered as a tablet or injection, enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety
After having lost a mean of 17.3% of their bodyweight on semaglutide and 2.0% on placebo at 68 weeks, they regained 11.6% and 1.9% of weight, resulting in net losses of 5.6% and 0.1% at week 120
When administered under medical supervision, GLP-1 injections are HC-approved, effective, and tailored to your specific health needs